Kanjinti

Indicated For

HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

About This Medication

# Amgen SupportPlus Patient Guide: How to Get Kanjinti at Low or No Cost ## About Kanjinti (Trastuzumab-anns) Kanjinti is a biosimilar medication used to treat HER2-overexpressing breast cancer. It is indicated for adjuvant (post-surgical) treatment of node-positive or node-negative breast cancer as part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. As a biosimilar to Herceptin (trastuzumab), Kanjinti offers patients an alternative option for their cancer treatment. ## Who Qualifies for Amgen SupportPlus Amgen SupportPlus is designed to help patients access Kanjinti regardless of their current financial situation or insurance type. The program recognizes that every patient has unique needs and offers personalized financial support and resources. **Primary eligibility includes:** - Patients with private or commercial insurance who need assistance with co-payments - Uninsured patients who may qualify for referrals to independent nonprofit patient assistance foundations - Patients seeking guidance on medication access and affordability The program does not have strict income thresholds that automatically disqualify patients. Instead, Amgen SupportPlus works with each patient individually to determine what resources and support options are available. ## Insurance Requirements and Coverage Amgen SupportPlus primarily serves patients with private or commercial insurance coverage. If you have commercial insurance, the program can help you: - Verify your insurance coverage for Kanjinti - Navigate prior authorization requirements - Access co-pay assistance programs - Understand your out-of-pocket costs **If you are uninsured or underinsured:** Amgen SupportPlus can provide information about independent nonprofit foundations that may be able to help you access Kanjinti. Eligibility for these nonprofit programs is based on each foundation's specific criteria. Amgen provides this information as a courtesy but does not control these independent programs. ## How to Apply for Amgen SupportPlus There are two convenient ways to enroll in Amgen SupportPlus: **Option 1: Phone Enrollment** - Call Amgen SupportPlus at **(866) 264-2778** - Available Monday through Friday, 9:00 AM to 8:00 PM ET - A representative can answer your questions and enroll you over the phone **Option 2: Online Enrollment** - Download the Amgen SupportPlus Enrollment Form from AmgenSupportPlus.com - Complete the form with your personal information, including: - Full name and date of birth - Contact information (phone number and email) - Street address and ZIP code - Gender (optional) - Alternate contact or caregiver information (if applicable) - Fax the completed form to **(1-888-407-9787)** **Important Privacy Note:** By enrolling in Amgen SupportPlus, you consent to Amgen processing your health data for program administration, including activities related to your condition or treatment, co-pay card programs, insurance coverage verification, nurse partner support, and disease management support. You may withdraw your consent at any time using the methods listed in the enrollment form. ## What Happens After You Apply Once you enroll in Amgen SupportPlus, you will be connected with an **Amgen Nurse Partner** who will: - Provide personalized support throughout your treatment - Offer guidance on resources that may help lower your out-of-pocket medication costs - Help you stay on track with your medication regimen - Answer questions about the Amgen SupportPlus program - Assist with benefit verification and insurance-related issues For healthcare providers and reimbursement specialists, Amgen SupportPlus also offers: - Assistance with patient coverage verification - Support with prior authorization requests - Co-pay program information - Reimbursement counseling ## Timeline and Medication Delivery While specific processing timelines are not publicly detailed, Amgen SupportPlus representatives work to expedite enrollment and connect patients with resources as quickly as possible. When you call or submit your enrollment form, representatives can often provide immediate information about your eligibility and next steps. For questions about ordering and accessing Kanjinti, you can also contact Amgen directly at **(1-800-77-AMGEN (1-800-772-6436)**. ## What If Your Application Is Denied If you are not eligible for Amgen SupportPlus co-pay assistance, the program can still help by: - Providing information about independent nonprofit patient assistance foundations - Connecting you with resources based on your specific situation - Offering guidance on alternative support options Remember that eligibility for nonprofit foundation programs is determined by each organization's individual criteria, and Amgen provides referral information as a courtesy. ## Biosimilar Alternatives If Kanjinti is not accessible to you, **Herceptin (trastuzumab)** is the original biologic medication that Kanjinti is based on. Both medications contain the same active ingredient and are used for the same breast cancer indications. Your healthcare provider can discuss whether Herceptin or other treatment options might be appropriate for your situation. ## Important Disclaimer This guide provides general information about Amgen SupportPlus and Kanjinti. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with your healthcare provider about your specific medical condition and treatment options. Eligibility for all programs, including independent nonprofit patient assistance, is subject to individual criteria and program requirements. Amgen SupportPlus representatives can provide detailed information about your specific eligibility and available resources. ## Contact Information Summary - **Amgen SupportPlus Phone:** (866) 264-2778 (Monday-Friday, 9 AM-8 PM ET) - **Enrollment Form Fax:** (1-888-407-9787) - **Amgen General Inquiries:** (1-800-772-6436) - **Website:** AmgenSupportPlus.com and Kanjinti.com

Program information last verified: March 30, 2026